Biodexa Pharmaceuticals PLC, a public limited liability company incorporated in the laws of England and Wales on September 12, 2014, known as Midatech, is a specialty pharmaceutical company focused on the development and commercialization of a variety of therapeutic products, using its nanotechnology and sustained-release technology to enhance the delivery of medicines in critical diseases and meet medical needs. These diseases include diabetes, certain cancers such as liver, pancreas, ovarian and brain (glioblastoma), and neurological/ophthalmic conditions. Midatech's strategy is to develop partners in rare cancers and other indications, keep its products in-house, and accelerate its business growth through strategic acquisitions of complementary products and technologies. 

Biodexa Pharmaceuticals PLC has initiated support activities for Familial Adenomatous Polyposis (FAP) patients and treatment centers in France. The biopharmaceutical company is developing innovative products for the treatment or prevention of gastrointestinal cancers. Biodexa has held its first round table meeting in Paris to share experience and expertise with patients, patient advocacy groups, and clinicians to improve outcomes and quality of life for FAP patients. This initiative is in addition to making eRapa available through an Early Access Program and Named Patient prescribing.Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) has launched a series of support activities for Familial Adenomatous Polyposis (FAP) patients and treatment centers in France. The company, which focuses on developing innovative therapies for gastrointestinal cancers, recently held its first round table meeting in Paris to facilitate knowledge exchange among patients, advocacy groups, and clinicians. The initiative aims to enhance treatment outcomes and improve the quality of life for individuals affected by <a href="https://biodexapharma.com/positive-statistically-significant-phase-2-clinical-trial-results-of-biodexas-newly-licensed-erapa-in-familial-adenomatous-polyposis-fap-scheduled-for-presentation-at-the-2024-dige/">statistically significant phase 2 results</a>.This effort complements Biodexa’s ongoing clinical development of eRapa, a proprietary oral formulation of rapamycin, which has demonstrated statistically significant results in a Phase 2 trial for FAP. The trial reported an 83% non-progression rate at six months and a <a href="https://biodexapharma.com/positive-statistically-significant-phase-2-clinical-trial-results-of-biodexas-newly-licensed-erapa-in-familial-adenomatous-polyposis-fap-scheduled-for-presentation-at-the-2024-dige/">24% reduction in polyp burden</a> (p=0.04). The company is currently conducting a Phase III trial, the Serenta study, which is <a href="https://www.clinicaltrialsarena.com/news/biodexa-trial-fap-treatment/">placebo-controlled and involves 168 participants</a> across multiple global sites.In addition to clinical trials, eRapa is available in France through an Early Access Program and Named Patient prescribing, allowing patients to access the treatment outside of formal clinical trials. These programs are intended to provide therapeutic options for patients while further data is collected.Biodexa’s strategy reflects its broader mission to address unmet medical needs in rare and complex diseases. The company continues to advance its pipeline, which includes eRapa for FAP and other gastrointestinal conditions, tolimidone for type 1 diabetes, and MTX110 for rare brain cancers.

Midatech Pharma

Biodexa Initiates Support Activities for FAP Patients in France

Biodexa Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced its first patient support roundtable in Paris, France, as part of its efforts to improve outcomes and quality of life for familial adenomatous polyposis (FAP) patients. The event aims to facilitate the exchange of experience and expertise between patients, patient advocacy groups, and clinicians. This initiative complements Biodexa's previous efforts, which included making eRapa available to FAP patients.Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) has announced the first patient support roundtable in Paris, France, aimed at enhancing outcomes and quality of life for individuals with familial adenomatous polyposis (FAP). The event is designed to foster dialogue among patients, advocacy groups, and clinicians to share <a href="https://biodexapharma.com/biodexa-announces-filing-of-cta-in-europe-for-phase-3-serenta-trial-in-familial-adenomatous-polyposis-fap/">insights and experiences related</a> to FAP management and treatment.This initiative aligns with Biodexa’s ongoing efforts to address the unmet medical needs of FAP patients. The company has previously advanced its eRapa program, a proprietary oral formulation of rapamycin, into Phase 3 clinical trials for FAP. The Serenta trial (NCT06950385) is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of eRapa in FAP patients. The Clinical Trial Application (CTA) for the trial was filed with the European Medicines Agency (EMA), with <a href="https://biodexapharma.com/biodexa-announces-filing-of-cta-in-europe-for-phase-3-serenta-trial-in-familial-adenomatous-polyposis-fap/">begin enrollment in late 2025</a>.FAP is a rare, inherited condition characterized by the development of numerous colorectal polyps, which, if untreated, nearly always progress to colorectal cancer. Current treatment options are limited to surgical interventions, highlighting the <a href="https://biodexapharma.com/biodexa-announces-filing-of-cta-in-europe-for-phase-3-serenta-trial-in-familial-adenomatous-polyposis-fap/">need for less invasive therapeutic alternatives</a>.Biodexa’s patient-focused initiatives reflect its broader strategy to develop innovative therapies for rare and complex diseases. The company’s pipeline includes eRapa, tolimidone for type 1 diabetes, and MTX110 for rare brain cancers, supported by <a href="https://biodexapharma.com/biodexa-announces-filing-of-cta-in-europe-for-phase-3-serenta-trial-in-familial-adenomatous-polyposis-fap/">proprietary drug delivery technologies</a>.

Biodexa Expands Patient Support for Familial Adenomatous Polyposis in France

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) has filed with the U.S. Securities and Exchange Commission (SEC) to register the resale of 2,560,000 American Depositary Shares (ADSs) by selling shareholders, according to <a href="https://www.stocktitan.net/sec-filings/BDRX/">a recent SEC filing</a>. The registration is part of the company’s ongoing efforts to facilitate the resale of shares previously issued under various financing arrangements.The ADSs in question represent ordinary shares of Biodexa, with each ADS corresponding to 400 ordinary shares. The filing does not indicate that the company is issuing new shares but rather that existing shareholders are seeking to register their shares for public resale. The company will not receive any proceeds from the resale of these shares by the <a href="https://www.stocktitan.net/sec-filings/BDRX/">selling shareholders</a>.This development follows a series of capital-raising activities by Biodexa, including registered direct offerings and private placements, which have been used to fund the company’s <a href="https://biodexapharma.com/biodexa-announces-7-million-of-gross-proceeds-from-warrant-exercises/">clinical development programs</a> and general corporate purposes. The company has previously utilized similar mechanisms to raise capital, including the issuance of warrants and pre-funded warrants, which have been <a href="https://www.stocktitan.net/sec-filings/BDRX/">registered for resale</a> under applicable securities laws.The SEC filing is part of the company’s broader compliance with U.S. securities regulations and aims to ensure transparency for investors. The registration statement includes updated information about the company’s financial position and corporate developments, reflecting <a href="https://www.stocktitan.net/sec-filings/BDRX/">disclosures from recent filings</a> and annual reports.As of the latest available financial data, Biodexa reported a cash balance of approximately £3.81 million as of May 2023, with the company expecting its <a href="https://biodexapharma.com/biodexa-pharmaceuticals-plc-announces-us3-32-million-registered-direct-offering/">cash resources to remain sufficient</a> to fund operations into the first quarter of 2024. The company continues to focus on advancing its clinical-stage assets, including eRapa, MTX110, and tolimidone, across <a href="https://biodexapharma.com/biodexa-announces-7-million-of-gross-proceeds-from-warrant-exercises/">various therapeutic areas</a>.The resale registration does not indicate any immediate changes to the company’s financial strategy or clinical development plans. Investors are advised to review the full SEC filing for detailed terms and conditions related to the <a href="https://www.stocktitan.net/sec-filings/BDRX/">resale of the ADSs</a>.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1cd4b73dd7b4d001.png" alt="Biodexa Pharmaceuticals - files for resale of 2.56 mln ADSs by selling shareholders - SEC filing">

Biodexa

Biodexa Pharmaceuticals - files for resale of 2.56 mln ADSs by selling shareholders - SEC filing

Biodexa Pharmaceuticals has priced a $3.5 mln offering of shares and a private placement of warrants. The company plans to use the proceeds to fund development programs, working capital, and other corporate purposes. The stock is down 3.09% in overnight trading after closing Tuesday's trade at $2.91.Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) has priced a $3.5 million offering of shares and a private placement of warrants, with the proceeds intended to support development programs, working capital, and general corporate purposes. The stock has <a href="https://biodexapharma.com/announces-closing-of-5-0-million-registered-direct-offering-and-concurrent-private-placement/">declined by 3.09% in overnight</a> trading following Tuesday’s close at $2.91.Previously, the company completed a $5.0 million registered direct offering and concurrent private placement in July 2024, raising approximately $4.2 million in net proceeds after deducting fees and expenses. These funds were allocated toward its development programs, including <a href="https://biodexapharma.com/announces-closing-of-5-0-million-registered-direct-offering-and-concurrent-private-placement/">final match payment for $17 million</a> grant from the Cancer Prevention Research Institute of Texas (CPRIT) and the initiation of a Phase 3 clinical trial for eRapa in Familial Adenomatous Polyposis (FAP).The recent offering includes the issuance of pre-funded warrants and Series J and K warrants, with exercise prices and expiration terms varying by instrument. <a href="https://biodexapharma.com/announces-closing-of-5-0-million-registered-direct-offering-and-concurrent-private-placement/">Ladenburg Thalmann &amp; Co. Inc.</a> served as the sole placement agent for the offering.Biodexa, a clinical-stage biopharmaceutical company, is focused on developing innovative treatments for diseases with unmet medical needs, including <a href="https://biodexapharma.com/announces-closing-of-5-0-million-registered-direct-offering-and-concurrent-private-placement/">eRapa, tolimidone, and MTX110</a>. The company also <a href="https://biodexapharma.com/announces-closing-of-5-0-million-registered-direct-offering-and-concurrent-private-placement/">amended the exercise prices</a> of several existing warrant series in connection with the offering.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1cc1ea4f34571001.png" alt="Biodexa Pharmaceuticals Raises $3.5 Million Through Registered and Private Placements of Shares and Warrants">

Biodexa Pharmaceuticals Raises $3.5 Million Through Registered and Private Placements of Shares and Warrants

Biodexa Pharmaceuticals has received approval from Health Canada to expand its Phase 3 SERENTA trial of MTX230 (eRapa) in familial adenomatous polyposis (FAP) into Canada. The trial has enrolled 78 of its expected 168 patients and is currently being conducted at 29 active sites in the US and five European countries. The trial aims to evaluate the safety and efficacy of MT230 in high-risk FAP patients, with a primary outcome of progression-free survival.Biodexa Pharmaceuticals has received regulatory approval from Health Canada to expand its Phase 3 SERENTA trial of MTX230 (eRapa) for the treatment of familial adenomatous polyposis (FAP) into Canada. This expansion follows the trial’s ongoing progress in the United States and five European countries, where 78 of the anticipated 168 patients have already been enrolled. The trial is currently <a href="https://www.gastroenterologyadvisor.com/news/encapsulated-rapamycin-fast-tracked-for-familial-adenomatous-polyposis/">active at 29 sites</a> across these regions.The SERENTA trial is designed to assess the safety and efficacy of MTX230 in high-risk FAP patients, with the primary endpoint focused on progression-free survival. The drug, encapsulated rapamycin, has previously been granted <a href="https://www.gastroenterologyadvisor.com/news/encapsulated-rapamycin-fast-tracked-for-familial-adenomatous-polyposis/">fast-track designation for FAP</a>, indicating its potential to address an unmet medical need. Clinical data from the trial will be critical in determining whether MTX230 can offer a viable therapeutic option for patients with this hereditary condition.The expansion into Canada reflects Biodexa’s strategic approach to broadening the geographic scope of its clinical research, potentially accelerating data collection and regulatory pathways. Investors and stakeholders will be closely monitoring the trial’s progress and interim results as key indicators of the drug’s development trajectory.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1cc00437edded001.png" alt="Biodexa Pharmaceuticals Expands Phase 3 SERENTA Trial into Canada with 73 Patients Enrolled So Far">

BDRX News